fbpx

About Us

Fellows Research Alliance is a clinical trials management and consulting group dedicated to research and development in an effort to bring new and safer products to patients. Our staff consists of highly trained physicians and clinical research professionals with over 50 years of clinical research experience. Fellows Research Alliance is currently serving the Georgia and South Carolina Coastal Empire. Our clinical research team has an extensive and diverse background that is beneficial to the patient, the medical community and the pharmaceutical industry.

With a diverse team of physician investigators, Fellows Research Alliance has the capability to conduct many trials within different indications. Our physician investigators have clinical experience in internal medicine, women’s health, pediatrics, GI health, respiratory, infectious diseases, endocrinology, as well as many others.

Fellows Research Alliance is proud of the close working relationship with its physicians, patients and pharmaceutical sponsors, and the integrity of our staff. Since March, 2008, all of our principal investigators are Certified Physician Investigators through the ACRP/APPI. We are committed to providing outstanding patient care within the context of research and quality research data.

In October, 2012, Fellows Research Alliance has partnered with Southcoast Medical Group to conduct clinical trials.  This partnership will allow both companies to conduct a more diverse range of clinical trials in the Coastal Empire area.

Meet the Staff

Dwan Fellows

Dwan Fellows

President/CEO

Monique Thompson

Monique Thompson

Lead CCRC

Debra Walland, MD, FACOG, CPI

Debra Walland, MD, FACOG, CPI

Medical Director

Chris Fellows

Chris Fellows

CFO

Facebook Posts

1 month ago

fellowsresearch.com

Fellows Research is currently looking for volunteers for an important clinical trial for women who have had recurrent yeast infections. In the Savannah, GA area, call 912-355-4447. In the Bluffton/Hilton Head, SC area, call 843-837-5590. ... See MoreSee Less

View on Facebook

1 month ago

fellowsresearch.com

Fellows Research is currently looking for volunteers for an important clinical trial for women who have had recurrent yeast infections. In the Savannah, GA area, call 912-355-4447. In the Bluffton/Hilton Head, SC area, call 843-837-5590. ... See MoreSee Less

View on Facebook

1 month ago

fellowsresearch.com
View on Facebook

2 months ago

fellowsresearch.com

Call is now for more information 912-355-4447 ... See MoreSee Less

View on Facebook

2 months ago

fellowsresearch.com

Incidence Of Precancerous Cervical Lesions Containing HPV Has Declined Significantly In US, Study Suggests.

MedPage Today (2/21) reports research by CDC investigators suggests that “the incidence of precancerous cervical lesions containing human papillomavirus (HPV) declined significantly from 2008 to 2014, as did the HPV strains that cause most cervical cancers.” The lower incidence “coincided with the introduction of the quadrivalent HPV vaccine, which targets HPV16/18, and the CIN2+ finding added to previous evidence suggesting a decrease in cervical precancerous lesions, reported Nancy McClung, PhD, RN, of the CDC in Atlanta, and colleagues.” The research “also provided the first evidence that HPV vaccination leads to ‘herd protection,’ as rates of HPV16/18-positive CIN2+ specimens declined in vaccinated and unvaccinated individuals alike.” The findings were published online in Cancer Epidemiology, Biomarkers & Prevention.
... See MoreSee Less

View on Facebook

2 months ago

fellowsresearch.com
View on Facebook

3 months ago

fellowsresearch.com

Research Suggests Years-Long Menopause Symptoms May Lead To Elevated Breast Cancer Risk.
Reuters (1/17, Mathias) reports a study found “women who experience symptoms of menopause...for many years may be slightly more likely to develop breast cancer than women who never had these symptoms,” according to a study published in Menopause. The American College of Obstetricians and Gynecologists (ACOG) says “so called vasomotor symptoms – such as hot flashes and night sweats – are the most commonly reported menopausal symptoms, occurring in up to 82 percent of women after natural menopause.” Among women in the study after 18-year follow-up, the risk for breast cancer “was 13 percent higher in the women with persistent vasomotor symptoms than in women who didn’t have these symptoms at all.”
... See MoreSee Less

View on Facebook

5 months ago

fellowsresearch.com

Postmenopausal Statin Use May Be Linked To Reduced Risk Of Ovarian Cancer.

In the International Journal of Cancer an article reports that research indicated “women who started taking a statin at the age of 50 or older had a significantly lower risk of developing any type of ovarian cancer over the next decade than non-statin users did. It is not a large decrease, but if you are on a statin, it is one more benefit to staying on it.
It is not recommended to start a statin drug only for the reason to lower the cancer risk.
... See MoreSee Less

View on Facebook

6 months ago

fellowsresearch.com

Yesterday, October 28, 2018 the United States Food and Drug Administration (FDA) granted approval for BIJUVA™ (estradiol and progesterone) capsules, 1mg/100mg, the first and only bio-identical* combination therapy of estradiol and progesterone taken once daily in a single oral capsule for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

We thank the Women volunteers who worked with us in the REPLENISH study for all your hard work and the support you provide to women’s health issues, particularly, menopause. We remain committed to the scientific development of innovative prescription products to help improve the overall health of your patients

The safety and efficacy of BIJUVA was evaluated in the pivotal REPLENISH Trial, a large, one-year, randomized, double-blind, placebo-controlled clinical trial that included 1,835 healthy menopausal women with an intact uterus. In a sub-population of symptomatic women with at least 50 moderate to severe hot flashes per week at baseline, BIJUVA was shown to help to reduce moderate to severe hot flashes due to menopause while also helping to reduce the risk for endometrial hyperplasia. The study results have been published in the journal Obstetrics & Gynecology.[1]

BIJUVA is the next generation of hormone therapy, developed to be identical in molecular structure to the hormones produced by the body. BIJUVA offers a proven balance of bio-identical estradiol to reduce moderate to severe hot flashes combined with bio-identical progesterone to reduce the risk of endometrial hyperplasia.

Now, healthcare professionals have a combination hormone therapy of bio-identical estradiol with bio-identical progesterone to offer menopausal women that has demonstrated both safety and efficacy for the treatment of moderate to severe hot flashes.

BIJUVA will be available for commercial distribution in Spring of 2019.
... See MoreSee Less

View on Facebook

9 months ago

fellowsresearch.com

Success. Thank you to our participants in the gout studies. After several years, the final statistics have shown that the study medication, lesinurad, has shown to be most effective in decreasingthe number of gout exascerbations. It also helps decrease the pain associated with flares. This medication could never have been tested effectively without your help. It is now available as a prescription. The brand name is Zurampic. ... See MoreSee Less

View on Facebook

9 months ago

fellowsresearch.com

HPV Test More Sensitive Than The Pap Smear, Study Indicates.

The Washington Post (7/3, McGinley) reported that research indicates “a test for HPV detects precancerous changes of the cervix earlier and more accurately than the Pap smear.” This “randomized, controlled study...showed that the human papillomavirus test is more sensitive than the Pap smear.” The findings were published in the Journal of the American Medical Association. The article added, “Most medical groups including the American Cancer Society and the American College of Obstetricians and Gynecologists recommend that women of average risk get both HPV tests and Pap smears every five years between age 30 and 65, though they say a Pap test alone every three years is an acceptable alternative.”
CNN (7/3, Howard) reported that Gina Ogilvie, who was lead author of the study, said, “The HPV virus is the cause of 99% of cervical cancers. By focusing on detecting the virus, we are then better able to determine which women have developed precancerous lesions and treat those earlier.”
The NPR (7/3, Watson) “Shots” blog reported that “studies like this one could lead to a change in guidelines, according to Dr. Chris Zahn, the vice president of practice for the American College of Obstetricians and Gynecologists.” In an email, he said, “This study adds evidence to those that evaluated use of HPV as a primary screening modality, and the findings support the use of HPV only as a primary screen.”
Also covering the story were the ABC News (7/4, Kalaichandran) website, Newsweek (7/4, Hugo), the NBC News (7/3, Fox) website, and Science News (7/3, Cunningham).

Thank you to all the hundreds of our patients who have participated in PAP/HPV studies over the years and continuing now. You really do make a difference. If you have not volunteered for the most recent study now going on, please call us and volunteer. It means so much for women now and the next generation!! 912 355-44447 Savannah or 843 837-5590 Bluffton,SC.
... See MoreSee Less

View on Facebook